IDEXX Laboratories, Inc. (IDXX) Stock Valuation — DCF Analysis
Medical - Diagnostics & Research · NASDAQ
Current Price
$560.88
Intrinsic Value
$593.63
+5.5% margin of safety
COMPETITIVE MOAT
↑Diagnostic Test Dominance
IDEXX holds a commanding position in veterinary diagnostics with a vast menu of proprietary tests. This extensive offering creates high switching costs for clinics heavily reliant on their integrated systems.
↑Integrated Workflow Solutions
The company's comprehensive suite of diagnostic instruments, software, and consumables creates a sticky ecosystem. This integration streamlines laboratory operations, making it difficult for competitors to displace.
↑Data Network Effects
IDEXX's large installed base generates a wealth of anonymized diagnostic data. This data fuels AI-driven insights and product development, further enhancing the value of their platform.
INVESTMENT RISKS
↓Emerging Competitive Technologies
New diagnostic platforms or point-of-care solutions could challenge IDEXX's market share. Competitors may offer more advanced or cost-effective alternatives, eroding their current dominance.
↓AI Integration Pace
While IDEXX is touting AI, the speed and effectiveness of its integration into existing workflows are critical. Failure to keep pace with AI advancements could leave them vulnerable to more agile competitors.
↓Regulatory Scrutiny
Changes in veterinary diagnostic regulations or approval processes could impact IDEXX's product pipeline and market access. Stringent oversight may slow innovation or introduce compliance burdens.
Base case
IDXX base case valuation
A base case discounted cash flow model for IDXX estimates an intrinsic value of about $593.63 per share, against a current price of $560.88. The model assumes 15.1% annual free cash flow growth, a 10.0% discount rate, and a 30x exit multiple.
Intrinsic Value
$593.63
Margin of safety
+5.5%
Expected annual return
+1.1%
Base case assumptions: 15.1% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-06-12.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the IDXX valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for IDEXX Laboratories, Inc. respond.
Open DCF Calculator for IDXXCompany Overview
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Financial Metrics — IDXX Stock Valuation Data
Revenue/Share (TTM)
$55.51
FCF/Share (TTM)
$13.48
ROIC (TTM)
40.7%
ROE (TTM)
70.9%
P/FCF
41.0x
EV/EBITDA
29.7x
FCF Yield
2.44%
Debt/Equity
0.69x
Based on trailing twelve-month data, IDXX shows a free cash flow per share of $13.48 and a ROIC of 40.7%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 41.0x and FCF yield of 2.44% are important context metrics when evaluating IDXX's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of IDXX?
IDEXX Laboratories, Inc. currently generates $13.48 in free cash flow per share. At the current price of $560.88, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is IDXX undervalued?
IDXX trades at a P/FCF ratio of 41.0x with a free cash flow yield of 2.44%. This elevated P/FCF suggests the market is pricing in significant future growth. However, whether IDXX is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value IDXX stock using DCF?
To perform a DCF valuation on IDEXX Laboratories, Inc.: (1) Start with the trailing free cash flow per share ($13.48) as the base, (2) project future FCF growth over 5-10 years based on Medical - Diagnostics & Research industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting IDXX's risk profile — with a debt-to-equity of 0.69x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to IDXX?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For IDEXX Laboratories, Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Diagnostics & Research trends, then discounting those amounts to today's dollars. IDXX's ROIC of 40.7% indicates strong capital efficiency, which supports higher growth assumptions in the DCF model.
How does WACC affect IDXX stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For IDXX, with a debt-to-equity ratio of 0.69x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 29.7x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See IDXX PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value IDXX with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.